查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947837

T細胞療法市場分析及預測（至2035年）：依類型、產品、服務、技術、應用、最終使用者、流程、階段及解決方案分類

T-cell Therapy Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Stage, Solutions
出版日期: | 出版商: Global Insight Services | 英文 341 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

T細胞療法市場預計將從2024年的52億美元成長到2034年的582億美元，複合年成長率約為29.1%。 T細胞治療方法市場利用基因工程改造的T細胞來增強免疫反應，並調動人體自身的免疫系統來靶向和摧毀癌細胞。 CAR-T和TCR療法的進步是推動該市場成長的主要因素，這些療法能夠提供個人化醫療，並展現出良好的療效。儘管癌症發病率的上升和技術創新正在推動市場成長，但高成本和複雜的生產流程仍然是該市場面臨的挑戰。

在癌症治療和個人化醫療的推動下，T細胞療法市場持續強勁成長。 CAR-T細胞療法是其中表現最強的細分市場，這主要得益於其在治療骨髓惡性腫瘤的成功。該領域的創新提高了療效和安全性，吸引了大量投資。 TCR-T細胞療法是表現第二強勁的細分市場，因其靶向固態腫瘤的潛力而備受關注。正在進行的臨床試驗和令人鼓舞的早期結果進一步鞏固了該細分市場的地位。異體T細胞療法已成為重點領域，與自體療法相比，它具有擴充性和更短的生產週期。同時，自體T細胞療法因其個人化治療方案和已建立的臨床療效而依然重要。生技公司和研究機構之間日益密切的合作正在加速研發進程。監管政策的進步也進一步推動了市場成長，為相關人員創造了盈利的機會。

市場區隔
類型 CAR-T細胞療法、TCR療法、TIL療法
產品 自製產品、類似產品
服務 製造服務、物流服務、諮詢服務
科技 基因編輯、細胞增生、細胞分離
應用領域 腫瘤學、感染疾病、自體免疫疾病
最終用戶 醫院、癌症研究中心和生物技術公司
流程 外生物過程，內生物過程
介紹 臨床試驗和商業部署
功能 治療和診斷
解決方案 客製化T細胞解決方案，標準化T細胞解決方案

T細胞療法市場正經歷顯著的變革，市佔率主要由少數幾家主要企業主導。由於新參與企業和創新產品的不斷湧現，定價策略競爭日益激烈。新型治療方法的推出正在重塑市場格局，並推動市場興趣和投資。各公司正致力於個人化醫療，以改善患者療效並擴大治療覆蓋範圍。這種充滿活力的市場環境正在催生出強大的下一代T細胞療法研發管線，以滿足尚未滿足的醫療需求。 T細胞療法市場的競爭日益激烈，各公司競相爭奪技術優勢。基準分析表明，投資專有技術和策略聯盟的公司正在獲得競爭優勢。監管的影響至關重要，嚴格的指導方針規範產品開發和市場准入。美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）是影響全球標準的關鍵監管機構。市場分析強調了有效利用這些法規結構對於確保成功商業化和永續成長的重要性。對於能夠巧妙運用技術進步和監管洞察的公司而言，這個市場環境充滿機會。

主要趨勢和促進因素：

受免疫療法和個人化醫療進步的推動，T細胞療法市場正經歷強勁成長。關鍵趨勢包括CAR-T細胞療法的日益普及，在治療骨髓惡性腫瘤展現出顯著療效。探索T細胞療法治療固體癌的臨床試驗不斷擴展，這是一項重要進展，有望推動其更廣泛的應用並改善患者預後。推動市場成長的因素包括癌症發生率的上升以及對創新治療方法的迫切需求。監管支持和加速核准流程也促進了新型治療方法進入市場。此外，生技公司與學術機構之間的合作正在加速研發進程，推動T細胞設計和製造技術的突破。新興市場蘊藏著大量機遇，這些市場醫療基礎設施的改善和生物技術領域投資的增加為T細胞療法的引入創造了有利條件。能夠順利通過法規核准流程並建立成本效益高的生產流程的公司，將更有機會在這個不斷擴大的市場中佔據優勢。此外，基因編輯技術和人工智慧的進步正在提高T細胞療法的精確性和有效性，進一步推動市場發展。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • CAR-T細胞療法
    • TCR療法
    • TIL療法
    • 其他
  • 市場規模及預測：依產品分類
    • 自製產品
    • 同種異體移植產品
    • 其他
  • 市場規模及預測：依服務分類
    • 製造服務
    • 物流服務
    • 諮詢服務
    • 其他
  • 市場規模及預測：依技術分類
    • 基因編輯
    • 細胞增殖
    • 細胞分離
    • 其他
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 感染疾病
    • 自體免疫疾病
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 癌症研究中心
    • 生技公司
    • 其他
  • 市場規模及預測：依製程分類
    • 體外處理
    • 生物過程
    • 其他
  • 市場規模及預測：依發展狀況
    • 臨床試驗
    • 商業部署
    • 其他
  • 市場規模及預測：依功能分類
    • 治療
    • 診斷
    • 其他
  • 市場規模及預測：按解決方案分類
    • 客製化T細胞解決方案
    • 標準化T細胞溶液
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Adaptimmune Therapeutics
  • Atara Biotherapeutics
  • Autolus Therapeutics
  • Bellicum Pharmaceuticals
  • Bluebird Bio
  • Cellectis
  • Celularity
  • Genocea Biosciences
  • Iovance Biotherapeutics
  • Kiadis Pharma
  • Marker Therapeutics
  • Mustang Bio
  • Poseida Therapeutics
  • Sorrento Therapeutics
  • TCR2 Therapeutics
  • Tessa Therapeutics
  • Turnstone Biologics
  • Unum Therapeutics
  • Ziopharm Oncology
  • Celyad Oncology

第9章：關於我們

簡介目錄
Product Code: GIS21392

T-cell Therapy Market is anticipated to expand from $5.2 billion in 2024 to $58.2 billion by 2034, growing at a CAGR of approximately 29.1%. The T-cell Therapy Market encompasses treatments that harness the body's immune system to target and destroy cancer cells, utilizing engineered T-cells to enhance immune response. This market is driven by advancements in CAR-T and TCR therapies, offering personalized medicine with promising efficacy. Increasing cancer prevalence and technological innovations are propelling growth, while challenges include high costs and complex manufacturing processes.

The T-cell Therapy Market is experiencing robust expansion, driven by advancements in cancer treatment and personalized medicine. The CAR-T cell therapy segment leads in performance, due to its success in treating hematological malignancies. Innovations in this segment are enhancing efficacy and safety profiles, attracting significant investment. The second highest performing segment is TCR-T cell therapy, which is gaining traction for its potential in targeting solid tumors. This segment is bolstered by ongoing clinical trials and promising early results. The allogeneic T-cell therapy sub-segment is emerging as a key area of interest, offering scalability and reduced production times compared to autologous therapies. Meanwhile, the autologous T-cell therapy sub-segment remains relevant, benefiting from its customized approach and established clinical outcomes. Increasing collaboration between biotech firms and research institutions is accelerating development timelines. Regulatory advancements are further facilitating market growth, creating lucrative opportunities for stakeholders.

Market Segmentation
TypeCAR-T Cell Therapy, TCR Therapy, TIL Therapy
ProductAutologous Products, Allogeneic Products
ServicesManufacturing Services, Logistics Services, Consulting Services
TechnologyGene Editing, Cell Expansion, Cell Isolation
ApplicationOncology, Infectious Diseases, Autoimmune Disorders
End UserHospitals, Cancer Research Centers, Biotechnology Companies
ProcessEx Vivo Process, In Vivo Process
DeploymentClinical Trials, Commercial Deployment
FunctionalityTherapeutic, Diagnostic
SolutionsCustom T-Cell Solutions, Standardized T-Cell Solutions

The T-cell therapy market is witnessing significant evolution, with market share being predominantly held by a few key players. Pricing strategies are becoming more competitive due to the influx of new entrants and innovative product launches. The introduction of novel therapies is reshaping the landscape, driving interest and investment. Companies are focusing on personalized medicine, enhancing patient outcomes and expanding the therapeutic scope. This dynamic environment is fostering a robust pipeline of next-generation T-cell therapies poised to address unmet medical needs. Competition in the T-cell therapy market is intensifying, with firms vying for technological superiority. Benchmarking reveals that companies investing in proprietary technologies and strategic collaborations are gaining a competitive edge. Regulatory influences are pivotal, with stringent guidelines shaping product development and market entry. The U.S. FDA and European Medicines Agency are leading regulatory bodies influencing global standards. The market analysis emphasizes the importance of navigating these regulatory frameworks to ensure successful commercialization and sustained growth. The landscape is ripe with opportunities for those adept at leveraging technological advancements and regulatory insights.

Geographical Overview:

The T-cell therapy market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the market, driven by advanced healthcare infrastructure and substantial investments in biotechnology. The presence of leading pharmaceutical companies and a strong focus on research and development further bolster the region's dominance. Europe follows, with significant investments in healthcare innovation fostering a thriving market for T-cell therapies. The region's regulatory environment supports clinical trials and accelerates the approval process, enhancing market growth. In Asia Pacific, the market is expanding rapidly, fueled by increasing healthcare expenditure and government initiatives promoting advanced therapies. Emerging countries like China and India are becoming vital growth pockets, with rising demand for innovative cancer treatments. Latin America and the Middle East & Africa are also gaining traction. These regions are recognizing the potential of T-cell therapies in addressing unmet medical needs and are investing in healthcare infrastructure to support market expansion.

The T-cell Therapy Market is navigating complex geopolitical landscapes and supply chain challenges, particularly in Japan, South Korea, China, and Taiwan. Global tariffs and trade tensions have necessitated strategic pivots in these nations, with Japan and South Korea enhancing domestic biomanufacturing capabilities to mitigate reliance on foreign imports. China is accelerating its biopharmaceutical innovation, seeking self-sufficiency amidst export restrictions. Taiwan, while a pivotal player in biotechnological advancements, faces geopolitical vulnerabilities due to US-China frictions. The parent market is experiencing robust growth globally, driven by advancements in personalized medicine and increasing cancer prevalence. By 2035, the market is expected to flourish, contingent on resilient supply chains and international collaborations. Middle East conflicts could indirectly affect supply chains through volatile energy prices, impacting operational costs and timelines.

Key Trends and Drivers:

The T-cell therapy market is experiencing robust growth, propelled by advancements in immunotherapy and personalized medicine. Key trends include the increasing adoption of CAR-T cell therapies, which have shown remarkable efficacy in treating hematological malignancies. The expansion of clinical trials exploring T-cell therapies for solid tumors marks a significant development, promising broader applications and improved patient outcomes. Drivers of market growth encompass the rising prevalence of cancer and the urgent need for innovative treatment options. Regulatory support and expedited approval processes are also facilitating the rapid entry of new therapies into the market. Additionally, collaborations between biotechnology firms and academic institutions are accelerating research and development efforts, leading to breakthroughs in T-cell engineering and manufacturing. Opportunities abound in emerging markets, where healthcare infrastructure improvements and growing investment in biotechnology are creating fertile ground for T-cell therapy adoption. Companies that can navigate regulatory pathways and establish cost-effective production processes are well-positioned to capitalize on these expanding markets. Furthermore, advancements in gene editing technologies and artificial intelligence are set to enhance the precision and efficacy of T-cell therapies, driving the market forward.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Functionality
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 CAR-T Cell Therapy
    • 4.1.2 TCR Therapy
    • 4.1.3 TIL Therapy
    • 4.1.4 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Autologous Products
    • 4.2.2 Allogeneic Products
    • 4.2.3 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Manufacturing Services
    • 4.3.2 Logistics Services
    • 4.3.3 Consulting Services
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Gene Editing
    • 4.4.2 Cell Expansion
    • 4.4.3 Cell Isolation
    • 4.4.4 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Infectious Diseases
    • 4.5.3 Autoimmune Disorders
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Cancer Research Centers
    • 4.6.3 Biotechnology Companies
    • 4.6.4 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Ex Vivo Process
    • 4.7.2 In Vivo Process
    • 4.7.3 Others
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 Clinical Trials
    • 4.8.2 Commercial Deployment
    • 4.8.3 Others
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Therapeutic
    • 4.9.2 Diagnostic
    • 4.9.3 Others
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Custom T-Cell Solutions
    • 4.10.2 Standardized T-Cell Solutions
    • 4.10.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Functionality
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Functionality
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Functionality
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Functionality
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Functionality
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Functionality
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Functionality
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Functionality
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Functionality
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Functionality
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Functionality
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Functionality
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Functionality
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Functionality
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Functionality
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Functionality
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Functionality
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Functionality
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Functionality
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Functionality
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Functionality
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Functionality
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Functionality
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Functionality
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Adaptimmune Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Atara Biotherapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Autolus Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bellicum Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Bluebird Bio
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Cellectis
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Celularity
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Genocea Biosciences
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Iovance Biotherapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Kiadis Pharma
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Marker Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Mustang Bio
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Poseida Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Sorrento Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 TCR2 Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Tessa Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Turnstone Biologics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Unum Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Ziopharm Oncology
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Celyad Oncology
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us